Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Income from Continuing Operations for 10 years, with the latest figure at 22592000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 164.57% year-over-year to 22592000.0; the trailing twelve-month figure through Mar 2026 stood at 73058000.0 (up 887.6% YoY), and the FY2025 full-year result was 59005000.0, up 266.12% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 22592000.0, up from 14199000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 224093000.0 in Q3 2022, with the low at 90632000.0 in Q4 2022.
• Historically, Income from Continuing Operations has averaged 2362529.41 across 5 years, with a median of 3908000.0 in 2024.
• Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 126.1% — and 2025, when it soared 1269.6%.
• Kiniksa Pharmaceuticals International's Income from Continuing Operations stood at 90632000.0 in 2022, then rose by 8.39% to 83032000.0 in 2023, then surged by 98.54% to 1214000.0 in 2024, then soared by 1269.6% to 14199000.0 in 2025, then surged by 59.11% to 22592000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 22592000.0 (Q1 2026), 14199000.0 (Q4 2025), and 18435000.0 (Q3 2025), per Business Quant data.